JP2011515073A - ヒト化抗Ｃ５ａＲ抗体 - Google Patents

ヒト化抗Ｃ５ａＲ抗体 Download PDF

Info

Publication number
JP2011515073A
JP2011515073A JP2010547002A JP2010547002A JP2011515073A JP 2011515073 A JP2011515073 A JP 2011515073A JP 2010547002 A JP2010547002 A JP 2010547002A JP 2010547002 A JP2010547002 A JP 2010547002A JP 2011515073 A JP2011515073 A JP 2011515073A
Authority
JP
Japan
Prior art keywords
antibody
seq
cells
amino acid
c5ar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010547002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515073A5 (https=
Inventor
ウィットフェルド，ピーター
ザアラ，デビット
マッカイ，チャールズ
Original Assignee
ジーツー インフラメイション プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーツー インフラメイション プロプライエタリー リミテッド filed Critical ジーツー インフラメイション プロプライエタリー リミテッド
Publication of JP2011515073A publication Critical patent/JP2011515073A/ja
Publication of JP2011515073A5 publication Critical patent/JP2011515073A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010547002A 2008-02-20 2009-02-19 ヒト化抗Ｃ５ａＲ抗体 Pending JP2011515073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6653908P 2008-02-20 2008-02-20
US61/066,539 2008-02-20
PCT/AU2009/000184 WO2009103113A1 (en) 2008-02-20 2009-02-19 HUMANIZED ANTI-C5aR ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014092573A Division JP6034826B2 (ja) 2008-02-20 2014-04-28 ヒト化抗Ｃ５ａＲ抗体

Publications (2)

Publication Number Publication Date
JP2011515073A true JP2011515073A (ja) 2011-05-19
JP2011515073A5 JP2011515073A5 (https=) 2012-04-05

Family

ID=40984994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010547002A Pending JP2011515073A (ja) 2008-02-20 2009-02-19 ヒト化抗Ｃ５ａＲ抗体
JP2014092573A Expired - Fee Related JP6034826B2 (ja) 2008-02-20 2014-04-28 ヒト化抗Ｃ５ａＲ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014092573A Expired - Fee Related JP6034826B2 (ja) 2008-02-20 2014-04-28 ヒト化抗Ｃ５ａＲ抗体

Country Status (14)

Country Link
US (3) US8268972B2 (https=)
EP (2) EP2254911B1 (https=)
JP (2) JP2011515073A (https=)
KR (1) KR20100117120A (https=)
CN (2) CN101970494B (https=)
AU (1) AU2009217224B2 (https=)
BR (1) BRPI0907532A2 (https=)
CA (1) CA2714296A1 (https=)
ES (1) ES2562627T3 (https=)
IL (1) IL207217A (https=)
MX (1) MX2010009190A (https=)
RU (1) RU2010138612A (https=)
WO (1) WO2009103113A1 (https=)
ZA (1) ZA201005348B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523829A (ja) * 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
JP2021527062A (ja) * 2018-06-07 2021-10-11 ケモセントリックス，インコーポレイティド ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
JP2022524449A (ja) * 2019-03-14 2022-05-02 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371861B1 (en) 2002-01-25 2017-08-09 Novo Nordisk A/S Monoclonal antibodies against extracellular loops of C5aR
MX2009001914A (es) * 2006-08-22 2009-03-31 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar con propiedades mejoradas.
EP2254911B1 (en) 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
RU2011101969A (ru) 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
WO2016096788A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Assay and method for determining cdc eliciting antibodies
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
CN107849133B (zh) 2015-05-04 2022-08-23 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
BR112019019595A2 (pt) * 2017-03-23 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
MX2020000435A (es) * 2017-07-14 2020-08-17 Cytomx Therapeutics Inc Anticuerpos anti-cd166 y usos de estos.
KR102355755B1 (ko) * 2017-12-14 2022-02-08 코카 크롬 인더스트리 컴퍼니 리미티드 냉각롤 및 그것을 사용한 열가소성 수지 시트의 제조 방법
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
CN109439662B (zh) * 2018-11-15 2020-09-01 北京大学第三医院 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2022207985A1 (en) * 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2024193714A1 (zh) * 2023-03-23 2024-09-26 科济生物医药（上海）有限公司 细胞免疫疗法的组合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535562A (ja) * 2002-01-25 2005-11-24 ジーツー セラピーズ リミテッド 抗Ｃ５ａＲ抗体及びその使用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279582A3 (en) * 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
SG41929A1 (en) 1992-09-25 1997-08-15 Commw Scient Ind Res Org Target binding polypeptide
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) * 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) * 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JPH11507513A (ja) 1995-06-05 1999-07-06 インサイト・ファーマスーティカルズ・インコーポレイテッド Ｃ５ａ様７膜貫通受容体
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
EP0972027A1 (en) 1997-01-31 2000-01-19 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2002231194A1 (en) 2000-11-07 2002-05-21 Genetics Institute, Llc G protein-coupled receptor protein and nucleic acid molecules and uses therefor
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2005060739A1 (en) * 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
AU2005226792A1 (en) * 2004-03-26 2005-10-06 Promics Pty Limited Treatment of neurological conditions using complement C5a receptor modulators
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US7649951B2 (en) 2006-08-16 2010-01-19 Harris Corporation System and method for communicating data using symbol-based randomized orthogonal frequency division multiplexing (OFDM) with applied frequency domain spreading
EP2061812A4 (en) 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd METHOD FOR THE PRODUCTION OF ANTIBODIES
MX2009001914A (es) 2006-08-22 2009-03-31 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar con propiedades mejoradas.
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
JP5314033B2 (ja) 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
EP2254911B1 (en) 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535562A (ja) * 2002-01-25 2005-11-24 ジーツー セラピーズ リミテッド 抗Ｃ５ａＲ抗体及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5010005502; ＮＡＴＵＲＥ　ＢＩＯＴＥＣＨＮＯＬＯＧＹ Ｖｏｌ．２４，　Ｎｏ．１０, 200610, ｐ．１２７９-１２８４ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523829A (ja) * 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
JP2021527062A (ja) * 2018-06-07 2021-10-11 ケモセントリックス，インコーポレイティド ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
JP2024114706A (ja) * 2018-06-07 2024-08-23 ケモセントリックス，インコーポレイティド ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
JP2022524449A (ja) * 2019-03-14 2022-05-02 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
JP7617012B2 (ja) 2019-03-14 2025-01-17 モルフォシス・アーゲー Ｃ５ａＲを標的とする抗体
JP2025069140A (ja) * 2019-03-14 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａＲを標的とする抗体
JP7842914B2 (ja) 2019-03-14 2026-04-08 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａＲを標的とする抗体

Also Published As

Publication number Publication date
EP2254911A4 (en) 2011-10-19
CN104193824A (zh) 2014-12-10
IL207217A (en) 2015-03-31
EP2254911B1 (en) 2015-11-25
US20130129721A1 (en) 2013-05-23
RU2010138612A (ru) 2012-03-27
ZA201005348B (en) 2011-10-26
CN101970494A (zh) 2011-02-09
JP6034826B2 (ja) 2016-11-30
US20110190477A1 (en) 2011-08-04
US8808701B2 (en) 2014-08-19
WO2009103113A1 (en) 2009-08-27
US8361468B2 (en) 2013-01-29
BRPI0907532A2 (pt) 2015-07-28
KR20100117120A (ko) 2010-11-02
AU2009217224A1 (en) 2009-08-27
US8268972B2 (en) 2012-09-18
ES2562627T3 (es) 2016-03-07
IL207217A0 (en) 2010-12-30
EP2826791A2 (en) 2015-01-21
MX2010009190A (es) 2010-09-10
EP2826791A3 (en) 2015-07-29
CA2714296A1 (en) 2009-08-27
JP2014193164A (ja) 2014-10-09
US20120315275A1 (en) 2012-12-13
CN101970494B (zh) 2015-01-21
AU2009217224B2 (en) 2014-09-11
EP2254911A1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
JP6034826B2 (ja) ヒト化抗Ｃ５ａＲ抗体
US20250092151A1 (en) Tetravalent anti-psgl-1 antibodies and uses thereof
DK2718322T3 (en) THERAPEUTIC ANTIBODIES
JP5162587B2 (ja) 改良された特性を持つ坑−Ｃ５ａＲ抗体
EA037397B1 (ru) Гуманизированные антитела к рецептору ccr7
US12304948B2 (en) Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141014